Toggle navigation
About Us
Portfolio
News
Contact Us
Lightchain Capital
Recent News
October 04, 2023
AI Proteins Announces the Appointment of Dr. Robert Stein to its Scientific Advisory Board
READ MORE
September 26, 2023
CareVet Partners with Blendvet™ & Hill’s Pet Nutrition to Launch Groundbreaking DEIB Initiative
READ MORE
September 26, 2023
NextRNA Therapeutics Strengthens Board of Directors with Appointment of Lori Friedman, PhD
READ MORE
September 09, 2023
Wugen Presents Initial Data from First-in-Human Phase 1/2 Trial of WU-CART-007 at the European Hematology Association (EHA) 2023 Congress
READ MORE
September 06, 2023
Geneoscopy CEO Andrew Barnell to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
READ MORE
September 05, 2023
C4 Therapeutics Announces Chief Financial Officer Succession
READ MORE
August 15, 2023
Wugen Begins First-in-Human Phase 1 Clinical Trial of WU-NK-101, its Lead Allogeneic Memory Natural Killer (NK) Cell Therapy for Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)
READ MORE
August 08, 2023
C4 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
READ MORE
August 08, 2023
AI Proteins Strengthens Leadership with Appointment of Noah D. Beerman as Chief Executive Officer and Industry Leader Mark J. Alles as Chairman of the Board of Directors
READ MORE
1
4
5
6
7
8
9
10
...
29
Contact Us
Lightchain Capital, LLC
PO Box 31729
St. Louis, MO 63131
Submit
4837,4748,4815,4823,4811,4819,4822,4748,4772,4748,4789,4811,4830,4819,4815,4760,4792,4760,4791,4825,4828,4817,4811,4824,4778,4825,4831,4830,4822,4825,4825,4821,4760,4813,4825,4823,4748,4758,4748,4829,4831,4812,4820,4815,4813,4830,4748,4772,4748,4781,4825,4824,4830,4811,4813,4830,4746,4784,4825,4828,4823,4748,4839
©2024 LIGHTCHAIN CAPITAL, LLC All Rights Reserved |
Privacy Policy
Website by
Tidal Media Group